BIBR 277 Capsules in Hypertensive Patients With Nephropathy
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
BIBR 277
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
Condition: Either of the following criteria is satisfied in laboratory tests:
- Presence of a renal parenchymal disorder such as chronic glomerulonephritis is confirmed (serum creatinine < 3.0 mg/dL)
- Presence of a renal function disorder (serum creatinine ≥ 1.5 mg/dL to < 3.0 mg/dL)
- Age: ≥ 20 years
- Sex: Either male or female
- Patient status: Either outpatients or inpatients. However, the patient status should remain unchanged throughout the study period
Blood pressure (BP):
- [Outpatients] The last 2 measurements of sitting BP out of at least 3 taken during the observation period (2 - 4 weeks) should be stable and a mean of the two measurements should be ≥160 mmHg for systolic BP (SBP) and ≥95 mmHg for diastolic BP (DBP)
- [Inpatients] The last 2 measurements of supine BP taken during the observation period (1 week) should be stable and a mean of the 2 measurements should be ≥ 150 mmHg for SBP and ≥ 90 mmHg for DBP
Exclusion Criteria:
- Renovascular hypertension
- Undergoing haemodialysis
- Severe hypertension (Diastolic BP ≥ 120 mmHg)
- Severe heart failure, angina pectoris, or history of myocardial infarction
- Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
- Symptoms of cerebrovascular disorder
- Serious hepatic dysfunction
- Uncontrolled diabetes
- Peptic ulcer
- History of hypersensitivity to drugs
- Hyperkalaemia
- Undergoing treatment with a digitalis preparation
- Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
- Otherwise judged ineligible by the investigator
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Single rising doses of BIBR 277
Arm Description
Outcomes
Primary Outcome Measures
Changes from baseline in hypertensive effect by investigator, using a 5-grade classification
Secondary Outcome Measures
Changes from baseline in blood pressure reduction
Rate of blood pressure normalisation
percentage of patients with < 150/90 mmHg
Changes from baseline in blood pressure / pulse rate
Usefulness assessment by investigator, using a 5- grade classification
Overall safety assessment by investigator, using a 5- grade classification
Number of patients with adverse events
Number of patients with abnormal changes in laboratory values
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02187484
Brief Title
BIBR 277 Capsules in Hypertensive Patients With Nephropathy
Official Title
BIBR 277 Capsules Clinical Study on Hypertension With Nephropathy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
August 1998 (undefined)
Primary Completion Date
August 1999 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The antihypertensive effect, safety and usefulness of treatment with BIBR 277 capsules were evaluated in hypertensive patients with nephropathy
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Single rising doses of BIBR 277
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BIBR 277
Primary Outcome Measure Information:
Title
Changes from baseline in hypertensive effect by investigator, using a 5-grade classification
Time Frame
8 weeks after start of treatment
Secondary Outcome Measure Information:
Title
Changes from baseline in blood pressure reduction
Time Frame
8 weeks after start of treatment
Title
Rate of blood pressure normalisation
Description
percentage of patients with < 150/90 mmHg
Time Frame
8 weeks after start of treatment
Title
Changes from baseline in blood pressure / pulse rate
Time Frame
8 weeks after start of treatment
Title
Usefulness assessment by investigator, using a 5- grade classification
Time Frame
8 weeks after start of treatment
Title
Overall safety assessment by investigator, using a 5- grade classification
Time Frame
8 weeks after start of treatment
Title
Number of patients with adverse events
Time Frame
Up to 12 weeks
Title
Number of patients with abnormal changes in laboratory values
Time Frame
Up to 8 weeks after start of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Condition: Either of the following criteria is satisfied in laboratory tests:
Presence of a renal parenchymal disorder such as chronic glomerulonephritis is confirmed (serum creatinine < 3.0 mg/dL)
Presence of a renal function disorder (serum creatinine ≥ 1.5 mg/dL to < 3.0 mg/dL)
Age: ≥ 20 years
Sex: Either male or female
Patient status: Either outpatients or inpatients. However, the patient status should remain unchanged throughout the study period
Blood pressure (BP):
[Outpatients] The last 2 measurements of sitting BP out of at least 3 taken during the observation period (2 - 4 weeks) should be stable and a mean of the two measurements should be ≥160 mmHg for systolic BP (SBP) and ≥95 mmHg for diastolic BP (DBP)
[Inpatients] The last 2 measurements of supine BP taken during the observation period (1 week) should be stable and a mean of the 2 measurements should be ≥ 150 mmHg for SBP and ≥ 90 mmHg for DBP
Exclusion Criteria:
Renovascular hypertension
Undergoing haemodialysis
Severe hypertension (Diastolic BP ≥ 120 mmHg)
Severe heart failure, angina pectoris, or history of myocardial infarction
Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
Symptoms of cerebrovascular disorder
Serious hepatic dysfunction
Uncontrolled diabetes
Peptic ulcer
History of hypersensitivity to drugs
Hyperkalaemia
Undergoing treatment with a digitalis preparation
Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
Otherwise judged ineligible by the investigator
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.266_U04-3224.pdf
Description
Related Info
Learn more about this trial
BIBR 277 Capsules in Hypertensive Patients With Nephropathy
We'll reach out to this number within 24 hrs